Unicycive Therapeutics Issues Shareholder Letter to Highlight Corporate Progress and Key Upcoming Milestones

January 23, 2024

https://www.globenewswire.com/news-release/2024/01/23/2813955/0/en/Unicycive-Therapeutics-Issues-Shareholder-Letter-to-Highlight-Corporate-Progress-and-Key-Upcoming-Milestones.html

– Topline Data from OLC Pivotal Trial Expected in Q2 2024 –
– OLC will target the multibillion-dollar hyperphosphatemia market –

LOS ALTOS, Calif., Jan. 23, 2024 (GLOBE NEWSWIRE) — Unicycive Therapeutics, Inc. (Nasdaq:UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company or “Unicycive”), today issued a letter to shareholders.

Read more at globenewswire.com

Related news for (UNCY)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.